This analysis examines the historical and forecast performance for Cephalon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Cephalon's performance against key rivals in the ethical pharmaceutical sector See how Cephalon's future performance relies heavily on the successful product lifecycle management of leading products Actiq and Provigil Learn how Cephalon has targeted the high-growth oncology therapy area, in order to diversify its portfolio.